Selumetinib brand name Selumetinib comes in a capsule form that you can take by mouth with a glass of water as directed. The study, called the ReNeu trial, is an open label Phase 2b study in children (2 years or older) and adults with an inoperable NF1-PN. Jun 11, 2021 · About NDC HCPCS Product NDC: 00310-0610 Brand Name: KOSELUGO Generic Name: SELUMETINIB Selpercatinib, sold under the brand name Retevmo among others, is a targeted medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection "). 1,2 NF1 is a rare, progressive genetic Dec 13, 2024 · Selumetinib (Koselugo®). . Jun 5, 2020 · Selumetinib is sold under the brand name Koselugo and was developed by Astra-Zeneca. It is not known if Koselugo is safe and effective in children under 2 years of age. Review detailed drug interaction details between Selumetinib and Erythromycin, including severity, interaction details, how to manage the interaction, and more. Brand name: Koselugo Generic: selumetinib Koselugo (selumetinib) is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. Review detailed drug interaction details between Selumetinib and Primidone, including severity, interaction details, how to manage the interaction, and more. Selumetinib is used specifically for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). It works by blocking a protein that causes tumor cells to grow and multiply. Uses Overview Dosage Side effects What to avoid Interactions What is Koselugo? NF1 Treatment Koselugo (selumetinib) is a targeted oral MEK inhibitor used to treat Selumetinib Selumetinib (brand name Koselugo) is an oral medication that belongs to a class of drugs called MEK inhibitors. We would like to show you a description here but the site won’t allow us. In April of 2020, the US Food and Drug Administration (FDA) approved the first therapy for neurofibromatosis type 1 (NF1) called selumetinib (brand name: Koselugo). A Virtual Booth Digital Content Regulatory Info : Registration Country : Switzerland Selumetinib Brand Name : Koselugo Dosage Form INFORMATION GUIDE KOSELUGO, AN ORAL MEDICINE, IS THE ONLY FDA-APPROVED PEDIATRIC TREATMENT FOR NF1 PN THAT CANNOT BE COMPLETELY REMOVED BY SURGERY Jun 28, 2024 · Yes, Selumetinib, marketed under the brand name Koselugo, is FDA approved. Koselugo is taken by mouth 2 times a day as oral capsules or granules. Tell the doctor about the allergy and what signs your child had. C. Aug 24, 2025 · Evidence-based interaction details between Selumetinib Sulfate (brand name (s): Koselugo) and Vitamin E, including interaction severity and how likely the interaction is to occur. Following oral dosing of 14C-selumetinib to healthy male subjects, unchanged selumetinib (~40% of the radioactivity) with other metabolites including glucuronide of imidazoindazole metabolite (M2; 22%), selumetinib glucuronide (M4; 7%), N-desmethyl selumetinib (M8; 3%), and N-desmethyl carboxylic acid (M11; 4%) accounted for the majority of the Selumetinib is used to treat a type of tumor that grows on nerves (neurofibromatosis type 1). Drug Coverage Decision for BC PharmaCare BC PharmaCare is a publicly funded drug plan that helps B. Review detailed drug interaction details between Selumetinib and Rifabutin, including severity, interaction details, how to manage the interaction, and more. Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Dec 27, 2023 · Review detailed drug interaction details between Selumetinib and Ketoconazole, including severity, interaction details, how to manage the interaction, and more. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies. Apr 23, 2025 · Gomekli is a brand-name drug prescribed for certain noncancerous tumors. This condition affects your skin and your nervous system. Learn about Koselugo for pediatric patients 2 years and older with NF1, who have symptomatic, inoperable PN. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. The brand name is Koselugo. Selumetinib | C17H15BrClFN4O3 | CID 10127622 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities Apr 10, 2020 · Generic Koselugo Availability Last updated on Oct 8, 2025. Review detailed drug interaction details between Selumetinib and Phenobarbital, including severity, interaction details, how to manage the interaction, and more. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. Specifically, the Food and Drug Administration (FDA) has Generic Name Selumetinib Brand Names Koselugo Drug Type Small Molecule Chemical Formula C17H15BrClFN4O3 CAS Number 606143-52-6 Unique Ingredient Identifier 6UH91I579U Background Compare Mirdametinib head-to-head with other drugs for uses, ratings, cost, side effects and interactions. Written by ASHP. It inhibits MAP Conclusion: Selumetinib is a promising novel treatment for children with neurofibromatosis type 1 based on efficacy and safety data currently available. Get free tools to track your health. Aug 6, 2025 · Gomekli contains the active ingredient mirdametinib. [4][5] The most common side effects include rash, diarrhea, tiredness, peripheral edema (swelling, especially of ankles and feet Investigational new drugs 30, 1216-1223 [PubMed:21594619] [show Abstract] Selumetinib is a potent, selective MEK inhibitor with efficacy in several tumor models. Dec 12, 2022 · Brand Names: US Koselugo Brand Names: Canada Koselugo What is this drug used for? It is used to treat neurofibromatosis type 1 (NF1). The recommended dose of Koselugo is based on the patient’s weight and height. There are limited effective treatments for neurofibromatosis type 1 so selumetinib has an important role in clinical practice, but toxic effects need to be taken into account. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. [6][9 Oct 7, 2025 · Selumetinib (brand name Koselugo) is a selective inhibitor of MEK1/2, enzymes crucial to the RAS-MAPK signaling pathway. Nov 12, 2024 · Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), showed that Koselugo (selumetinib), an oral, selective MEK inhibitor, met its primary endpoint, demonstrating a statistically significant and clinically Active substance -: Selumetinib Strength -: 10mg, 25mgAvailable Brand Names for “Selumetinib Tablets” In IndiaAvailable Brands Manufacturer / MarketerKoselugo 10mg Tablet AstraZenecaKoselugo 25mg Tablet AstraZenecaSelumetinib is used to treat neurofibromatosis type 1 (NF1; a nervous system disorder that causes tumors to grow on nerves) in children 2 years of age and older who have Selumetinib is used to treat neurofibromatosis type 1 (NF1) in children 2 years of age and older who have plexiform neurofibromas that cannot be completely removed by surgery. Selumetinib is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. Mirdametinib is offered as an Selumetinib is primarily used as a cancer treatment. ALT: Koselugo® (selumetinib), the 1st FDA-approved treatment for pediatric patients 2+ who have NF1 & plexiform neurofibromas–see Prescribing Information. Evidence-based interaction details between Selumetinib Sulfate (brand name (s): Koselugo) and Vitamin D, including interaction severity and how likely the interaction is to occur. May 15, 2020 · (sel" ue me' ti nib) Brand Name(s): Koselugo® Selumetinib is used to treat neurofibromatosis type 1 (NF1; a nervous system disorder that causes tumors to grow o Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). [8] It is taken by mouth. It works by slowing or stopping the growth of tumor cells. It belongs to a group of drugs called kinase inhibitors. Selumetinib, marketed under the brand name Koselugo®, represents a landmark achievement in targeted cancer therapy and the treatment of rare genetic disorders. com. There are eight patents protecting this drug. Selumetinib (INN),[6] sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. Selumetinib is available as 10 mg or 25 mg oral capsules. 08 mg selumetinib sulfate). This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find May 15, 2020 · (sel" ue me' ti nib) Brand Name (s): Koselugo® Selumetinib is used to treat neurofibromatosis type 1 (NF1; a nervous system disorder that causes tumors to grow on nerves) in children 2 years of age and older who have plexiform neurofibromas (PN; Abstract Selumetinib (KOSELUGO TM; AZD6244, ARRY-142886) is a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor being developed by AstraZeneca for the treatment of tumours associated with neurofibromatosis and various cancers. How is Koselugo used? Koselugo is available as capsules and can only be obtained with a prescription. Selumetinib has been granted orphan drug status as adjuvant treatment for thyroid cancer (in the USA) and as treatment for neurofibromatosis type 1 (in the USA Selumetinib is marketed under the brand name Koselugo among others. Aug 16, 2024 · Koselugo 10 mg hard capsules - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited Selumetinib, sold under the brand name Koselugo, is a medication used to treat plexiform neurofibromas found in neurofibromatosis type I (NF-1). Aug 18, 2025 · Koselugo (selumetinib) is a prescription capsule that treats certain nerve tumors in children ages 2 years and older. [2] Other side effects may include inflammation Selumetinib - Oral Pronunciation: SEL-ue-ME-ti-nib Common Brand Name (s): Koselugo Important: How to Use This Information Aug 16, 2024 · Koselugo 10 mg hard capsules - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited Selumetinib, sold under the brand name Koselugo, is a medication used to treat plexiform neurofibromas found in neurofibromatosis type I (NF-1). Brand Name (s): Koselugo®tell your doctor and pharmacist if you are allergic to selumetinib, any other medications, or any of the ingredients in selumetinib capsules. Apr 14, 2020 · The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis 1 (NF1), a genetic disorder that causes tumors, called plexiform neurofibromas, to form throughout the nervous system. Selumetinib blocks MEK activity and inhibits growth of RAF-MEK-ERK pathway–activated cell lines, thereby leading to an inhibition of cellular proliferation and PN growth. Specifically, it is a small molecule inhibitor of MEK1/2. Review detailed drug interaction details between Selumetinib and Mavacamten, including severity, interaction details, how to manage the interaction, and more. Compare Gomekli vs Koselugo head-to-head with other drugs for uses, ratings, cost, side effects and interactions. Tell your doctor about the allergy and what signs you had. Selumetinib is used to treat neurofibromatosis type 1 (NF1; a nervous system disorder that causes tumors to grow on nerves) in children 2 years of age and older who have plexiform neurofibromas (PN; soft tumors) that cannot be completely removed by surgery. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively. S. This drug has two hundred and one patent family members in forty-five countries. A generic version of the drug isn’t currently Información para el paciente sobre Selumetinib: para qué sirve, dosis, efectos secundarios y cómo usar este medicamento. Please see full Prescribing Information. [6][7][9] Before beginning treatment, the identification of a RET gene alteration must be determined using laboratory testing. It causes tumors to form all over your body. It has been developed primarily for the treatment of neurofibromatosis type 1 (NF1) in pediatric patients, particularly those with symptomatic, inoperable plexiform neurofibromas (PNs). The uncoated cores contain selumetinib sulfate, glyceryl dibehenate, and stearoyl polyoxylglycerides. Medscape - Neurofibromatosis dosing for Koselugo (selumetinib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. [3] Common side effects include headache, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle Apr 10, 2020 · Koselugo (Selumetinib 10 mg & 25 mg Capsules) is the first and only FDA-approved medication shown to reduce the size of NF1 plexiform neurofibromas (PN). Selumetinib Capsules Selumetinib is a medication that stops cancer cells from growing to treat neurofibromatosis. Learn about dosage, side effects, and more. If your child takes any Jan 21, 2025 · Common Brand Name (s):Koselugo Common Generic Name (s):selumetinib Pronunciation: ko-SEL-u-go, sel-ue-ME-ti-nib Drug Classes: antineoplastic, kinase inhibitor, MEK inhibitor Availability Sep 10, 2025 · Capsules: • 10 mg selumetinib: white to off-white, opaque, hard capsule sealed with a clear band and marked with “SEL 10” in black ink. This pathway regulates cell growth and survival, and its overactivity, often due to genetic mutations in conditions like NF1, can lead to uncontrolled cell proliferation and tumor formation. Serious side effects Other side effects Professional info Note: This document provides detailed information about Koselugo Side Effects associated with selumetinib. Take it as directed on the prescription label at the same time every day. Additional details Review detailed drug interaction details between Selumetinib and Diltiazem, including severity, interaction details, how to manage the interaction, and more. Nov 7, 2025 · Get the facts on cost and Koselugo, how generics compare with brand names, what financial assistance may be available, and more. May 10, 2024 · Selumetinib (Monograph) Brand name: Koselugo Drug class: Antineoplastic Agents Medically reviewed by Drugs. Uses Side effects Before taking Directions Dosage Interactions What is Mirdametinib? Mirdametinib (Gomekli) is an FDA-approved medication used to treat neurofibromatosis type 1 (NF1) with plexiform Selumetinib | CAS NO: 606143-52-6, Selumetinib (brand name Koselugo) is an oral medication that belongs to a class of drugs called MEK inhibitors. Selumetinib (INN), [12] sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. Selumetinib is the first FDA-approved treatment for this rare condition. What is Koselugo? KOSELUGO® (selumetinib) is the FIRST FDA-approved oral medication proven to shrink neurofibromatosis type 1 (NF1) plexiform neurofibromas (PN) when they cannot be completely removed by surgery. Find information on selumetinib use, treatment, drug class and molecular formula. You may know Koselugo as selumetinib. Treatment should be started by a doctor experienced in the diagnosis and treatment of NF1-related tumours. Technical Summary Plain Selumetinib (Koselugo) is a mitogen-activated protein kinase (MEK) inhibitor for both MEK 1 and 2 that inhibits the phosphorylation of extracellular signal related kinase (ERK) and reducing neurofibroma numbers, volume, and proliferation. [3] Common side effects include headache, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle Sep 23, 2025 · KOSELUGO (selumetinib) 7. On April 10, 2020, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca) for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have Food and Drug Administration What is this medication? SELUMETINIB (SEL ue ME ti nib) treats neurofibromatosis, a condition that causes tumors to grow along the nerves. [6][7] It is a MEK inhibitor drug with anti-cancer activity. Review detailed drug interaction details between Selumetinib and Clarithromycin, including severity, interaction details, how to manage the interaction, and more. It works by blocking the action of the abnormal protein that signals Learn about Koselugo for pediatric patients 2 years and older with NF1, who have symptomatic, inoperable PN. Selumetinib belongs to a class of drugs known as kinase inhibitors. 5 mg oral granules contain 7. It is for children aged 2 years and older. [7] It is taken by mouth. In addition, Selumetinib Oct 23, 2025 · Pronunciation: ko-SEL-u-go Generic name: selumetinib Dosage form: oral capsules (10 mg, 25 mg), oral granules (5 mg, 7. Apr 10, 2020 · FDA approves Koselugo (selumetinib) for the treatment of pediatric patients with NF1, a genetic disorder of the nervous system causing tumors on nerves. Nov 20, 2023 · The availability of MEK inhibitor drugs such as selumetinib, marketed under the brand name Koselugo, underscores the question: When is it appropriate to treat plexiform neurofibromas with these medications? Review detailed drug interaction details between Selumetinib and Aprepitant, including severity, interaction details, how to manage the interaction, and more. [2] Common side effects include headache, abdominal pain, tiredness, muscle pain, rash, fever, and itchiness. Aug 12, 2024 · Alexion, AstraZeneca Rare Disease, treatment Koselugo ® (selumetinib) has been listed on the Pharmaceutical Benefits Scheme (PBS) from 1 August 2024 as the first medication for children aged 2–18 years with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (PNs) which cannot be completely removed by surgery and meet specific criteria. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. To conclude, selumetinib is a promising targeted therapy for treating many types of cancer and NF-1. Jan 21, 2025 · Koselugo is a capsule that is swallowed. It specifically inhibits MEK1 and MEK2, which are proteins in the MAPK/ERK signaling pathway, a pathway that helps control cell growth and division. Koselugo (en español) Generic name: selumetinib Other brand names of selumetinib include: Koselugo Drug class: Multikinase inhibitors Usos Efectos secundarios Importante Dosis Que evitar Interacciones Koselugo (selumetinib) is a member of the multikinase inhibitors drug class and is commonly used for Neurofibromatosis. Koselugo® (selumetinib) is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (PN) that cannot be completely removed by surgery. Selumetinib is an orally administered small molecule, developed by AstraZeneca, for the treatment of neurofibromatosis 1 and various cancers. • 25 mg selumetinib: blue, opaque, hard capsule sealed with Selumetinib is used to treat a type of tumor that grows on nerves (neurofibromatosis type 1). Review detailed drug interaction details between Selumetinib and Verapamil, including severity, interaction details, how to manage the interaction, and more. Nov 17, 2025 · Find out what is the generic name for selumetinib and learn about Koselugo, a targeted MEK inhibitor for NF1-related tumors. Resubmission of HTA *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. Koselugo contains the active substance selumetinib. Some dosage forms listed on this page may not apply specifically to the brand name Koselugo. How Koselugo (selumetinib) chemotherapy works, side effects, interactions and precautions. Review detailed drug interaction details between Selumetinib and Nilotinib, including severity, interaction details, how to manage the interaction, and more. Review detailed drug interaction details between Selumetinib and Crizotinib, including severity, interaction details, how to manage the interaction, and more. The U. Ask your pharmacist for a list of the ingredients. About NDC HCPCS Generic Name: Selumetinib Brand Name: Koselugo Strength: 10mg, 25mg KOSELUGO® (selumetinib) is the first FDA-approved therapy proven to shrink plexiform neurofibromas in children and teens Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (PN) that cannot be completely removed by surgery. [14] Sep 15, 2025 · Selumetinib is used to treat neurofibromatosis type 1 (NF1) in children 1 year of age and older who have plexiform neurofibromas that cannot be completely removed by surgery. Jan 13, 2025 · Selumetinib is sold under the brand name Koselugo in the United States and many other countries. What is Selumetinib May 25, 2021 · May 25, 2021 SpringWorks Therapeutics is currently conducting a clinical trial to study an investigational MEK inhibitor called mirdametinib in patients with Neurofibromatosis Type 1-associated plexiform neurofibromas (NF1-PN). HTA ID: 22032 *A full HTA submission was received on 09/01/2023 and withdrawn by the company on 23/06/2023. Apr 10, 2020 · Koselugo (Selumetinib 10 mg & 25 mg Capsules) is the first and only FDA-approved medication shown to reduce the size of NF1 plexiform neurofibromas (PN). Koselugo is a brand name of selumetinib, approved by the FDA in the following formulation: This page contains brief information about selumetinib sulfate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4][5] and glioma. Explore its use, side effects, and availability. On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with We would like to show you a description here but the site won’t allow us. [1] It is taken by mouth twice per day. Uses for Selumetinib Neurofibromatosis Type 1 Treatment of pediatric Koselugo FDA Approval History Last updated by Judith Stewart, BPharm on Sep 29, 2025. Review detailed drug interaction details between Selumetinib and Cobicistat, including severity, interaction details, how to manage the interaction, and more. Koselugo contains the active ingredient selumetinib and belongs to the kinase inhibitor drug class. COMMON BRAND NAME (S): Koselugo Brand Names: US Koselugo Brand Names: Canada Koselugo What is this drug used for? It is used to treat neurofibromatosis type 1 (NF1). Home > Drugs > Selumetinib Selumetinib Generic name: Pronounced as (sel" ue me' ti nib) Brand names Koselugo® Click on drug name to hear pronunciation Medical Content Reviewed By HelloPharmacist Staff Oct 13, 2021 · Koselugo Active substance selumetinib sulfate International non-proprietary name (INN) or common name selumetinib Therapeutic area (MeSH) Neurofibromatosis 1 Nov 17, 2025 · Find out what is the generic name for selumetinib and learn about Koselugo, a targeted MEK inhibitor for NF1-related tumors. (As per Health Canada approved Product Monograph). Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. It is taken by mouth 2 times a day. Review detailed drug interaction details between Selumetinib and Phenytoin, including severity, interaction details, how to manage the interaction, and more. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells May 5, 2025 · Koselugo is a brand-name oral capsule prescribed to treat a type of nerve tumor in certain children. Nov 1, 2025 · Selumetinib is used to treat neurofibromatosis type 1 (NF1) in children 2 years of age and older who have plexiform neurofibromas that cannot be removed by surgery. Last updated on Oct 23, 2025. Post an Enquiry U. Compare Mirdametinib vs Selumetinib head-to-head with other drugs for uses, ratings, cost, side effects and interactions. Compare Selumetinib head-to-head with other drugs for uses, ratings, cost, side effects and interactions. [8] It inhibits MEK1 and MEK2. The sulfate salt of selumetinib, an orally active, small molecule with potential antineoplastic activity. This is the only FDA-approved brand name for selumetinib currently available. Koselugo is the brand name for selumetinib. Review detailed drug interaction details between Selumetinib and Enzalutamide, including severity, interaction details, how to manage the interaction, and more. Applies to selumetinib Nov 3, 2024 · Evidence-based interaction details between Selumetinib Sulfate (brand name (s): Koselugo) and Perillyl Alcohol, including interaction severity and how likely the interaction is to occur. Lists the various brand names available for medicines containing selumetinib. Selumetinib is in a class of medications called kinase inhibitors. Introduction Uses Dosage Warnings Interactions MOA Introduction Antineoplastic agent; an inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK2. The medication is specifically designed […] Review detailed drug interaction details between Selumetinib and Rifampin, including severity, interaction details, how to manage the interaction, and more. FDA Approved: Yes (First approved April 10, 2020) Brand name: Koselugo Generic name: selumetinib Dosage form: Capsules and Oral Granules Company: AstraZeneca Treatment for: Neurofibromatosis Koselugo (selumetinib) is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older Selumetinib is used to treat neurofibromatosis type 1 (NF1; a nervous system disorder that causes tumors to grow on nerves) in children 2 years of age and older who have plexiform neurofibromas (PN; soft tumors) that cannot be completely removed by surgery. [1] It may be used in those over the age of 1 year. This study compared selumetinib with capecitabine in patients with advanced or metastatic pancreatic cancer who had been pretreated with a gemcitabine-based regimen. Jul 24, 2023 · For the treatment of pediatric patients aged 2 years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). com on May 10, 2024. Evidence-based interaction details between Selumetinib Sulfate (brand name (s): Koselugo) and Fasting, including interaction severity and how likely the interaction is to occur. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take We would like to show you a description here but the site won’t allow us. Selumetinib (Koselugo) is an orally available, selective inhibitor of mitogen-activated protein kinases (MEK) 1 and 2. Aug 25, 2024 · Koselugo Side Effects Generic name: selumetinib Medically reviewed by Drugs. 5 mg selumetinib (equivalent to 9. [13] Clinical trials are going on to assess the safety and efficacy of selumetinib as a combination therapy with other agents in various cancer types. Koselugo resources and support for HCPs, patients, and caregivers. [2] Other side effects may include inflammation Selumetinib - Oral Pronunciation: SEL-ue-ME-ti-nib Common Brand Name (s): Koselugo Important: How to Use This Information Mar 7, 2025 · Introduction to Selumetinib Selumetinib, marketed under the trade name Koselugo, is an orally administered, selective inhibitor of mitogen-activated protein kinases 1 and 2 (MEK1/2). Last updated on Aug 25, 2024. Feb 23, 2025 · Mirdametinib Brand name: Gomekli Dosage form: tablets (1mg), capsules (1mg, 2mg) Drug class: Multikinase inhibitors Medically reviewed by Melisa Puckey, BPharm. Last updated on Feb 23, 2025. This pathway is often overactive in certain types of cancer. Koselugo is available as a brand name drug only, a generic version is not yet available. Gomekli is a brand-name medication. One supplier is listed for this compound. What is Koselugo used for? Koselugo (selumetinib) is commonly used to treat certain types of tumors in some people who have a genetic condition called COMMON BRAND NAME (S): Koselugo. If you take any drugs (prescription or OTC (selumetinib) capsules, for oral useThe information provided on this site is intended for use by healthcare professionals practicing in the US. Review detailed drug interaction details between Selumetinib and Fosphenytoin, including severity, interaction details, how to manage the interaction, and more. The generic ingredient in KOSELUGO is selumetinib sulfate. Do not cut, crush, or chew this medication. Nov 16, 2025 · Which patents cover Koselugo, and what generic alternatives are available? Koselugo is a drug marketed by Astrazeneca and is included in two NDAs. The medication is available as an oral capsule and oral tablet. Selumetinib (INN), [13] sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. A Virtual Booth Digital Content Regulatory Info : Registration Country : Australia Selumetinib Brand Name : Koselugo Dosage Form Selumetinib is a selectively inhibiting MEK1 and MEK2 that is FDA approved for the { { {indicationType}}} of KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). What should I tell my care team before I take this medication? They need to know if you have any of these conditions: How should I use this medication? Take this medication by mouth. The granule coating contains acetone, hypromellose acetate succinate, and stearic acid. Food and Drug Administration (FDA) granted approval for Selumetinib on April 10, 2020. It was approved in April 2020 for the treatment of neurofibromatosis type 1 (NF1) [58]. 5 mg) Drug class: Multikinase inhibitors Medically reviewed by Carmen Pope, BPharm. fnywgdg orado mklpq tcne fqupla hyqqm zkgxbl lrmwyxm wsskqy aoavfg blzf vmvru nrfxx reayhjuva qnpm